Heartflow Inc. (HTFL) reached an all-time high of $51.26 per share in morning trading on September 2, 2026, extending a steep rally that has seen the stock climb more than 73% year-to-date and roughly 110% over the past six months.
The gain followed second-quarter results that significantly outperformed Wall Street expectations. Heartflow reported an adjusted loss per share of $0.07, far better than the negative $0.19 consensus estimate, while revenue surged 48% year-over-year to $64.1 million. That topped both Stifel’s projection of $56.7 million and the broader consensus of $56.6 million.
Growth was driven by rising demand for the company’s coronary artery disease diagnostics platform, alongside strong momentum in its plaque analysis and fractional flow reserve computed tomography (FFRCT) businesses.
Stifel responded by raising its price target on Heartflow shares from $40.00 to $45.00, maintaining a Buy rating on the stock.
Despite the rally, some valuation metrics flagged caution. According to InvestingPro analysis, Heartflow trades near its 52-week high and appears overvalued relative to its Fair Value estimate. The platform noted 13 additional ProTips for HTFL and highlighted research coverage spanning more than 1,400 U.S. equities.
The one-year return stands at approximately 61.22%, underscoring the speed of the stock’s recovery and expansion over the past two years.
